![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Merck Nets Third FDA Approval for Keytruda as Cancer Treatment
Merck Nets Third FDA Approval for Keytruda as Cancer Treatment
Merck received its third FDA-approved use for Keytruda on Monday: a post-chemotherapy treatment for patients head and neck squamous cell carcinoma.
The approval covers a 200 mg fixed dose every three weeks for patients with recurrent or metastatic cancer that already have undergone platinum-containing chemotherapy.
Keytruda already is approved to treat melanoma and lung cancer.
Upcoming Events
-
21Oct